A vaccine made with RNA for adults whose glioblastoma has come back
Original title: RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people, not a treatment doctors can give yet.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a new vaccine in adults whose glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary has returned.
Who this trial is for. This trial is for adults with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary that has come back. It tests a vaccine made from RNA held in tiny fat particles.
Where it stands. The trial is checking two things. First, whether the vaccine can be made for each person. Second, how safe it is, and what dose people can take without too many side effects. The trial has not reported results.
What this means, and what it doesn't
What it could mean: Nothing is proven here yet. Still, someone with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary that came back could ask their care team about this study. The care team can say if it might fit.
What it doesn't mean: This does not mean the vaccine works. A trial is a test, not a proven treatment. Joining a study is not a promise of help. And it is not a cure.
Source: ClinicalTrials.gov, September 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.